Jose Leis, MD, Oncology, Phoenix, AZ, Mayo Clinic Hospital

JoseFranciscoLeisMDPhD

Oncology Phoenix, AZ

Hematologic Oncology

Physician

Dr. Leis is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Leis' full profile

Already have an account?

Summary

  • Dr. Jose Leis is an oncologist in Scottsdale, AZ and is affiliated with Mayo Clinic Hospital. He received his medical degree from University of Arizona College of Medicine - Tucson and has been in practice 31 years. He specializes in hematologic oncology and is experienced in acute and chronic leukemias, lymphoma, myelodysplasia, myelofibrosis, and bone marrow transplantation.

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Hematology, 1989 - 1993
  • University of California San Diego
    University of California San DiegoResidency, Internal Medicine, 1986 - 1989
  • University of Arizona College of Medicine - Tucson
    University of Arizona College of Medicine - TucsonClass of 1986

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2007 - 2021
  • OR State Medical License
    OR State Medical License 1997 - Present
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Press Ganey Top Provider Recognition Award Office of Mayo Clinic Experience, Mayo Clinic Arizona, 2020
  • Top Doctors:Arizona State Castle Connolly, 2013-2020
  • Top Faculty Award Mayo School of Continuous Professional Development, 2011-2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
    Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphoc...
    Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis
    Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Management of Steroid Resistant Acute and Chronic GVHD: Are We Making Progress? 
    CIBMTR and ASBMT BMT Tandem Meeting, Salt Lake City, UT - 2/2018
  • CLL: What To Do After BTK Inhibitor Therapy Fails 
    Great Debates & Updates in Hematologic Malignancies, New York, NY - 4/2018
  • How I Treat Newly Diagnosed, Relapsed, and Transformed CLL Patients 
    American Society of Hematology (ASH) Meeting on Hematologic Malignancies, Chicago, IL - 9/2019
  • Join now to see all

Professional Memberships

Hospital Affiliations